Abstract

Use of Anthrax Vaccine in Response to Terrorism: Supplemental Recommendations of the Advisory Committee on Immunization Practices

Highlights

  • SINCE 1994, THE AVAILABILITY OF INcreasingly effective antiretroviral drugs for both the prevention of perinatal human immunodeficiency virus (HIV)

  • Project indicated that the majority of women will accept HIV testing if it is rec2680 ommended by their health-care provider

  • Chart abstraction can document only prenatal HIV testing recorded in maternal medical records; without such documentation, clinicians might not be aware of the need to offer effective perinatal interventions to infected women and their HIVexposed infants

Read more

Summary

HIV Testing Among

SINCE 1994, THE AVAILABILITY OF INcreasingly effective antiretroviral drugs for both the prevention of perinatal human immunodeficiency virus (HIV). States and Canadian provinces have implemented three different prenatal HIVtesting approaches To assess their effectiveness, CDC reviewed prenatal HIVantibody testing rates associated with these approaches. Two states (New York and Connecticut) require HIV testing of newborns whose mothers were not tested during pregnancy. Network review of medical records in seven counties in the Rochester area indicated that the proportion of pregnant women who received a prenatal HIV test increased from 52% of 438 charts during January 1998–July 1999 to 83% of 112 charts during August-December. PRAMS data for 1999 indicated that the proportion of women statewide who reported having received an HIV test during pregnancy increased from 69% of 758 women during JanuaryJuly to 93% of 502 during AugustDecember. Statewide analyses of prenatal testing reported on newborn metabolic screening forms from all live-born infants, New York reported prenatal HIV-testing rates of 89%.

FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION
Data from the Perinatal Guidelines
Environments From
National Institute for Occupational
The guidelines also recommend that the emergency capabilities of the systems’
Committee on Immunization
Prevention of Anthrax by PEP
Additional Considerations
Findings
Recommendations for Additional Research

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.